{"id":"https://openalex.org/W2010859136","doi":"https://doi.org/10.1007/s00280-014-2476-y","title":"Development and antitumor activity of a BCL-2 targeted single-stranded DNA oligonucleotide","display_name":"Development and antitumor activity of a BCL-2 targeted single-stranded DNA oligonucleotide","publication_year":2014,"publication_date":"2014-05-15","ids":{"openalex":"https://openalex.org/W2010859136","doi":"https://doi.org/10.1007/s00280-014-2476-y","mag":"2010859136","pmid":"https://pubmed.ncbi.nlm.nih.gov/24832107","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/4077254"},"language":"en","primary_location":{"id":"doi:10.1007/s00280-014-2476-y","doi":"https://doi.org/10.1007/s00280-014-2476-y","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s00280-014-2476-y","pdf_url":"https://link.springer.com/content/pdf/10.1007/s00280-014-2476-y.pdf","source":{"id":"https://openalex.org/S117498271","display_name":"Cancer Chemotherapy and Pharmacology","issn_l":"0344-5704","issn":["0344-5704","1432-0843"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Chemotherapy and Pharmacology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://link.springer.com/content/pdf/10.1007/s00280-014-2476-y.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5010727781","display_name":"Wendi V. Rodrigueza","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210165057","display_name":"ProNAi Therapeutics (United States)","ror":"https://ror.org/05rzyfd75","country_code":"US","type":"company","lineage":["https://openalex.org/I4210165057"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Wendi V. Rodrigueza","raw_affiliation_strings":["ProNAi Therapeutics, Inc., Plymouth, MI, USA, wrodrigueza@pronai.com","ProNAi Therapeutics, Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ProNAi Therapeutics, Inc., Plymouth, MI, USA, wrodrigueza@pronai.com","institution_ids":["https://openalex.org/I4210165057"]},{"raw_affiliation_string":"ProNAi Therapeutics, Inc","institution_ids":["https://openalex.org/I4210165057"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012601023","display_name":"Michael J. Woolliscroft","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210165057","display_name":"ProNAi Therapeutics (United States)","ror":"https://ror.org/05rzyfd75","country_code":"US","type":"company","lineage":["https://openalex.org/I4210165057"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael J. Woolliscroft","raw_affiliation_strings":["ProNAi Therapeutics, Inc., Plymouth, MI, USA","ProNAi Therapeutics, Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ProNAi Therapeutics, Inc., Plymouth, MI, USA","institution_ids":["https://openalex.org/I4210165057"]},{"raw_affiliation_string":"ProNAi Therapeutics, Inc","institution_ids":["https://openalex.org/I4210165057"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024637436","display_name":"Abdul-Shukkur Ebrahim","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I185443292","display_name":"Wayne State University","ror":"https://ror.org/01070mq45","country_code":"US","type":"education","lineage":["https://openalex.org/I185443292"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Abdul-Shukkur Ebrahim","raw_affiliation_strings":["Wayne State University, Detroit, MI, USA","Wayne State University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Wayne State University, Detroit, MI, USA","institution_ids":["https://openalex.org/I185443292"]},{"raw_affiliation_string":"Wayne State University","institution_ids":["https://openalex.org/I185443292"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084425832","display_name":"Robert W. Forgey","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210165057","display_name":"ProNAi Therapeutics (United States)","ror":"https://ror.org/05rzyfd75","country_code":"US","type":"company","lineage":["https://openalex.org/I4210165057"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert Forgey","raw_affiliation_strings":["ProNAi Therapeutics, Inc., Plymouth, MI, USA","ProNAi Therapeutics, Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ProNAi Therapeutics, Inc., Plymouth, MI, USA","institution_ids":["https://openalex.org/I4210165057"]},{"raw_affiliation_string":"ProNAi Therapeutics, Inc","institution_ids":["https://openalex.org/I4210165057"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059658046","display_name":"Patrick J. McGovren","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210165057","display_name":"ProNAi Therapeutics (United States)","ror":"https://ror.org/05rzyfd75","country_code":"US","type":"company","lineage":["https://openalex.org/I4210165057"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Patrick J. McGovren","raw_affiliation_strings":["ProNAi Therapeutics, Inc., Plymouth, MI, USA","ProNAi Therapeutics, Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ProNAi Therapeutics, Inc., Plymouth, MI, USA","institution_ids":["https://openalex.org/I4210165057"]},{"raw_affiliation_string":"ProNAi Therapeutics, Inc","institution_ids":["https://openalex.org/I4210165057"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030322815","display_name":"Gerold Endert","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Gerold Endert","raw_affiliation_strings":["Novosom AG, Halle, Germany","Novosom AG"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novosom AG, Halle, Germany","institution_ids":[]},{"raw_affiliation_string":"Novosom AG","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100869042","display_name":"Andreas Wagner","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210104119","display_name":"Polymun (Austria)","ror":"https://ror.org/016rjax45","country_code":"AT","type":"company","lineage":["https://openalex.org/I4210104119"]}],"countries":["AT"],"is_corresponding":false,"raw_author_name":"Andreas Wagner","raw_affiliation_strings":["Polymun Scientific GmbH, Klosterneuburg, Austria","Polymun Scientific GmbH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Polymun Scientific GmbH, Klosterneuburg, Austria","institution_ids":["https://openalex.org/I4210104119"]},{"raw_affiliation_string":"Polymun Scientific GmbH","institution_ids":["https://openalex.org/I4210104119"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034476099","display_name":"Danielle D. Holewa","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210165057","display_name":"ProNAi Therapeutics (United States)","ror":"https://ror.org/05rzyfd75","country_code":"US","type":"company","lineage":["https://openalex.org/I4210165057"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Danielle Holewa","raw_affiliation_strings":["ProNAi Therapeutics, Inc., Plymouth, MI, USA","ProNAi Therapeutics, Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ProNAi Therapeutics, Inc., Plymouth, MI, USA","institution_ids":["https://openalex.org/I4210165057"]},{"raw_affiliation_string":"ProNAi Therapeutics, Inc","institution_ids":["https://openalex.org/I4210165057"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038465132","display_name":"Amro Aboukameel","orcid":"https://orcid.org/0009-0009-9912-2887","observed_orcids":["https://orcid.org/0009-0009-9912-2887"]},"institutions":[{"id":"https://openalex.org/I185443292","display_name":"Wayne State University","ror":"https://ror.org/01070mq45","country_code":"US","type":"education","lineage":["https://openalex.org/I185443292"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Amro Aboukameel","raw_affiliation_strings":["Wayne State University, Detroit, MI, USA","Wayne State University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Wayne State University, Detroit, MI, USA","institution_ids":["https://openalex.org/I185443292"]},{"raw_affiliation_string":"Wayne State University","institution_ids":["https://openalex.org/I185443292"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Richard D. Gill","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210165057","display_name":"ProNAi Therapeutics (United States)","ror":"https://ror.org/05rzyfd75","country_code":"US","type":"company","lineage":["https://openalex.org/I4210165057"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Richard D. Gill","raw_affiliation_strings":["ProNAi Therapeutics, Inc., Plymouth, MI, USA","ProNAi Therapeutics, Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ProNAi Therapeutics, Inc., Plymouth, MI, USA","institution_ids":["https://openalex.org/I4210165057"]},{"raw_affiliation_string":"ProNAi Therapeutics, Inc","institution_ids":["https://openalex.org/I4210165057"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110438741","display_name":"Charles L. Bisgaier","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210165057","display_name":"ProNAi Therapeutics (United States)","ror":"https://ror.org/05rzyfd75","country_code":"US","type":"company","lineage":["https://openalex.org/I4210165057"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Charles L. Bisgaier","raw_affiliation_strings":["ProNAi Therapeutics, Inc., Plymouth, MI, USA","ProNAi Therapeutics, Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ProNAi Therapeutics, Inc., Plymouth, MI, USA","institution_ids":["https://openalex.org/I4210165057"]},{"raw_affiliation_string":"ProNAi Therapeutics, Inc","institution_ids":["https://openalex.org/I4210165057"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011464371","display_name":"Richard Adam Messmann","orcid":"https://orcid.org/0000-0002-2112-0277","observed_orcids":["https://orcid.org/0000-0002-2112-0277"]},"institutions":[{"id":"https://openalex.org/I4210165057","display_name":"ProNAi Therapeutics (United States)","ror":"https://ror.org/05rzyfd75","country_code":"US","type":"company","lineage":["https://openalex.org/I4210165057"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Richard A. Messmann","raw_affiliation_strings":["ProNAi Therapeutics, Inc., Plymouth, MI, USA","ProNAi Therapeutics, Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ProNAi Therapeutics, Inc., Plymouth, MI, USA","institution_ids":["https://openalex.org/I4210165057"]},{"raw_affiliation_string":"ProNAi Therapeutics, Inc","institution_ids":["https://openalex.org/I4210165057"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058753628","display_name":"Christopher E. Whitehead","orcid":"https://orcid.org/0000-0002-1223-0001","observed_orcids":["https://orcid.org/0000-0002-1223-0001"]},"institutions":[{"id":"https://openalex.org/I4210165057","display_name":"ProNAi Therapeutics (United States)","ror":"https://ror.org/05rzyfd75","country_code":"US","type":"company","lineage":["https://openalex.org/I4210165057"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Christopher E. Whitehead","raw_affiliation_strings":["ProNAi Therapeutics, Inc., Plymouth, MI, USA","ProNAi Therapeutics, Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ProNAi Therapeutics, Inc., Plymouth, MI, USA","institution_ids":["https://openalex.org/I4210165057"]},{"raw_affiliation_string":"ProNAi Therapeutics, Inc","institution_ids":["https://openalex.org/I4210165057"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039359398","display_name":"El\u017cbieta Izbicka","orcid":"https://orcid.org/0000-0002-8994-1303","observed_orcids":["https://orcid.org/0000-0002-8994-1303"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Elzbieta Izbicka","raw_affiliation_strings":["BTNS, LLC, San Antonio, TX, USA","BTNS, LLC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BTNS, LLC, San Antonio, TX, USA","institution_ids":[]},{"raw_affiliation_string":"BTNS, LLC","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017648006","display_name":"Robert T. Streeper","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Robert Streeper","raw_affiliation_strings":["BTNS, LLC, San Antonio, TX, USA","BTNS, LLC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BTNS, LLC, San Antonio, TX, USA","institution_ids":[]},{"raw_affiliation_string":"BTNS, LLC","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Michael C. Wick","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210119066","display_name":"South Texas Accelerated Research Therapeutics","ror":"https://ror.org/01scs7915","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210119066"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael C. Wick","raw_affiliation_strings":["South Texas Accelerated Research Therapeutics (START), LLC, San Antonio, TX, USA","South Texas Accelerated Research Therapeutics (START), LLC, San Antonio, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"South Texas Accelerated Research Therapeutics (START), LLC, San Antonio, TX, USA","institution_ids":["https://openalex.org/I4210119066"]},{"raw_affiliation_string":"South Texas Accelerated Research Therapeutics (START), LLC, San Antonio, USA","institution_ids":["https://openalex.org/I4210119066"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042369547","display_name":"Gabriela M. Stiegler","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210104119","display_name":"Polymun (Austria)","ror":"https://ror.org/016rjax45","country_code":"AT","type":"company","lineage":["https://openalex.org/I4210104119"]}],"countries":["AT"],"is_corresponding":false,"raw_author_name":"Gabriela Stiegler","raw_affiliation_strings":["Polymun Scientific GmbH, Klosterneuburg, Austria","Polymun Scientific GmbH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Polymun Scientific GmbH, Klosterneuburg, Austria","institution_ids":["https://openalex.org/I4210104119"]},{"raw_affiliation_string":"Polymun Scientific GmbH","institution_ids":["https://openalex.org/I4210104119"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038833981","display_name":"C.A. Stein","orcid":"https://orcid.org/0009-0001-1419-0197","observed_orcids":["https://orcid.org/0009-0001-1419-0197"]},"institutions":[{"id":"https://openalex.org/I129975664","display_name":"Albert Einstein College of Medicine","ror":"https://ror.org/05cf8a891","country_code":"US","type":"education","lineage":["https://openalex.org/I129975664","https://openalex.org/I4210112371"]},{"id":"https://openalex.org/I1335289525","display_name":"Montefiore Medical Center","ror":"https://ror.org/044ntvm43","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1335289525","https://openalex.org/I19772626"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"C. A. Stein","raw_affiliation_strings":["Montefiore Medical Center and the Albert Einstein College of Medicine, New York, NY, USA","Montefiore Medical Center and the Albert Einstein College of Medicine, New York, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Montefiore Medical Center and the Albert Einstein College of Medicine, New York, NY, USA","institution_ids":["https://openalex.org/I129975664","https://openalex.org/I1335289525"]},{"raw_affiliation_string":"Montefiore Medical Center and the Albert Einstein College of Medicine, New York, USA","institution_ids":["https://openalex.org/I129975664","https://openalex.org/I1335289525"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049638525","display_name":"David J. Monsma","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1317189400","display_name":"Van Andel Institute","ror":"https://ror.org/00wm07d60","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I1317189400"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David Monsma","raw_affiliation_strings":["Van Andel Research Institute, Grand Rapids, MI, USA","-, Van Andel Research Institute"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Van Andel Research Institute, Grand Rapids, MI, USA","institution_ids":["https://openalex.org/I1317189400"]},{"raw_affiliation_string":"-, Van Andel Research Institute","institution_ids":["https://openalex.org/I1317189400"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009017507","display_name":"Craig Paul Webb","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1317189400","display_name":"Van Andel Institute","ror":"https://ror.org/00wm07d60","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I1317189400"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Craig Webb","raw_affiliation_strings":["Van Andel Research Institute, Grand Rapids, MI, USA","-, Van Andel Research Institute"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Van Andel Research Institute, Grand Rapids, MI, USA","institution_ids":["https://openalex.org/I1317189400"]},{"raw_affiliation_string":"-, Van Andel Research Institute","institution_ids":["https://openalex.org/I1317189400"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020200197","display_name":"Mina Sooch","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210165057","display_name":"ProNAi Therapeutics (United States)","ror":"https://ror.org/05rzyfd75","country_code":"US","type":"company","lineage":["https://openalex.org/I4210165057"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mina P. Sooch","raw_affiliation_strings":["ProNAi Therapeutics, Inc., Plymouth, MI, USA","ProNAi Therapeutics, Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ProNAi Therapeutics, Inc., Plymouth, MI, USA","institution_ids":["https://openalex.org/I4210165057"]},{"raw_affiliation_string":"ProNAi Therapeutics, Inc","institution_ids":["https://openalex.org/I4210165057"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076762856","display_name":"Steffen Panzner","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Steffen Panzner","raw_affiliation_strings":["Novosom AG, Halle, Germany","Novosom AG"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novosom AG, Halle, Germany","institution_ids":[]},{"raw_affiliation_string":"Novosom AG","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101474379","display_name":"Ramzi M. Mohammad","orcid":"https://orcid.org/0000-0001-8332-5246","observed_orcids":["https://orcid.org/0000-0001-8332-5246"]},"institutions":[{"id":"https://openalex.org/I185443292","display_name":"Wayne State University","ror":"https://ror.org/01070mq45","country_code":"US","type":"education","lineage":["https://openalex.org/I185443292"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ramzi Mohammad","raw_affiliation_strings":["Wayne State University, Detroit, MI, USA","Wayne State University, Detroit USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Wayne State University, Detroit, MI, USA","institution_ids":["https://openalex.org/I185443292"]},{"raw_affiliation_string":"Wayne State University, Detroit USA","institution_ids":["https://openalex.org/I185443292"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078103055","display_name":"Neal C. Goodwin","orcid":"https://orcid.org/0000-0002-1117-1740","observed_orcids":["https://orcid.org/0000-0002-1117-1740"]},"institutions":[{"id":"https://openalex.org/I4210165057","display_name":"ProNAi Therapeutics (United States)","ror":"https://ror.org/05rzyfd75","country_code":"US","type":"company","lineage":["https://openalex.org/I4210165057"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Neal C. Goodwin","raw_affiliation_strings":["ProNAi Therapeutics, Inc., Plymouth, MI, USA","ProNAi Therapeutics, Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ProNAi Therapeutics, Inc., Plymouth, MI, USA","institution_ids":["https://openalex.org/I4210165057"]},{"raw_affiliation_string":"ProNAi Therapeutics, Inc","institution_ids":["https://openalex.org/I4210165057"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5065296584","display_name":"Ayad M Al-Katib","orcid":"https://orcid.org/0000-0002-5684-948X","observed_orcids":["https://orcid.org/0000-0002-5684-948X"]},"institutions":[{"id":"https://openalex.org/I185443292","display_name":"Wayne State University","ror":"https://ror.org/01070mq45","country_code":"US","type":"education","lineage":["https://openalex.org/I185443292"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ayad Al-Katib","raw_affiliation_strings":["Wayne State University, Detroit, MI, USA","Wayne State University, Detroit USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Wayne State University, Detroit, MI, USA","institution_ids":["https://openalex.org/I185443292"]},{"raw_affiliation_string":"Wayne State University, Detroit USA","institution_ids":["https://openalex.org/I185443292"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":7,"corresponding_author_ids":["https://openalex.org/A5010727781"],"corresponding_institution_ids":["https://openalex.org/I4210165057"],"apc_list":{"value":4390,"currency":"USD","value_usd":4390},"apc_paid":{"value":4390,"currency":"USD","value_usd":4390},"fwci":1.2117,"has_fulltext":true,"cited_by_count":27,"citation_normalized_percentile":{"value":0.76619273,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"74","issue":"1","first_page":"151","last_page":"166"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10725","display_name":"RNA Interference and Gene Delivery","score":0.9829000234603882,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10725","display_name":"RNA Interference and Gene Delivery","score":0.9829000234603882,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10294","display_name":"Cell death mechanisms and regulation","score":0.0066999997943639755,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10432","display_name":"DNA and Nucleic Acid Chemistry","score":0.0032999999821186066,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/bcl-2","display_name":"Bcl-2","score":0.8180000185966492},{"id":"https://openalex.org/keywords/antisense-oligonucleotides","display_name":"antisense oligonucleotides","score":0.9049999713897705},{"id":"https://openalex.org/keywords/dna-interference","display_name":"DNA interference","score":0.8190000057220459},{"id":"https://openalex.org/keywords/liposomal-drug-delivery","display_name":"liposomal drug delivery","score":0.6060000061988831},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.8569999933242798},{"id":"https://openalex.org/keywords/non-hodgkin-lymphoma","display_name":"non-Hodgkin lymphoma","score":0.8730000257492065},{"id":"https://openalex.org/keywords/melanoma","display_name":"melanoma","score":0.7480000257492065},{"id":"https://openalex.org/keywords/prostate-cancer","display_name":"prostate cancer","score":0.8349999785423279},{"id":"https://openalex.org/keywords/burkitt-lymphoma","display_name":"Burkitt lymphoma","score":0.984000027179718},{"id":"https://openalex.org/keywords/sequence-specificity","display_name":"sequence specificity","score":0.6190000176429749},{"id":"https://openalex.org/keywords/tumor-xenografts","display_name":"tumor xenografts","score":0.6079999804496765},{"id":"https://openalex.org/keywords/refractory-cancer","display_name":"refractory cancer","score":0.5440000295639038}],"concepts":[{"id":"https://openalex.org/C129312508","wikidata":"https://www.wikidata.org/wiki/Q133686","display_name":"Oligonucleotide","level":3,"score":0.74588543176651},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.7428067326545715},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.5475186705589294},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5434117913246155},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.49835801124572754},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.4502694606781006},{"id":"https://openalex.org/C155887181","wikidata":"https://www.wikidata.org/wiki/Q5053552","display_name":"Cationic liposome","level":4,"score":0.4439234137535095},{"id":"https://openalex.org/C552990157","wikidata":"https://www.wikidata.org/wiki/Q7430","display_name":"DNA","level":2,"score":0.43791481852531433},{"id":"https://openalex.org/C185154212","wikidata":"https://www.wikidata.org/wiki/Q410454","display_name":"Liposome","level":2,"score":0.4271705746650696},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.4033786654472351},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.39918386936187744},{"id":"https://openalex.org/C153911025","wikidata":"https://www.wikidata.org/wiki/Q7202","display_name":"Molecular biology","level":1,"score":0.38297179341316223},{"id":"https://openalex.org/C111599444","wikidata":"https://www.wikidata.org/wiki/Q213901","display_name":"Genetic enhancement","level":3,"score":0.3265025019645691},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.2541743814945221},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.2403893768787384},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.16334274411201477},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D002470","descriptor_name":"Cell Survival","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D004277","descriptor_name":"DNA, Single-Stranded","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D004277","descriptor_name":"DNA, Single-Stranded","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D004277","descriptor_name":"DNA, Single-Stranded","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D004277","descriptor_name":"DNA, Single-Stranded","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D004339","descriptor_name":"Drug Compounding","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004355","descriptor_name":"Drug Stability","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008081","descriptor_name":"Liposomes","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008807","descriptor_name":"Mice, Inbred BALB C","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008819","descriptor_name":"Mice, Nude","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009838","descriptor_name":"Oligodeoxyribonucleotides","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D009838","descriptor_name":"Oligodeoxyribonucleotides","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D009838","descriptor_name":"Oligodeoxyribonucleotides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D009838","descriptor_name":"Oligodeoxyribonucleotides","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D011897","descriptor_name":"Random Allocation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014677","descriptor_name":"Pharmaceutical Vehicles","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016373","descriptor_name":"DNA, Antisense","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D016373","descriptor_name":"DNA, Antisense","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D016373","descriptor_name":"DNA, Antisense","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D016373","descriptor_name":"DNA, Antisense","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D016513","descriptor_name":"Mice, SCID","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019253","descriptor_name":"Proto-Oncogene Proteins c-bcl-2","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D019253","descriptor_name":"Proto-Oncogene Proteins c-bcl-2","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D019253","descriptor_name":"Proto-Oncogene Proteins c-bcl-2","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D020868","descriptor_name":"Gene Silencing","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D023041","descriptor_name":"Xenograft Model Antitumor Assays","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D024506","descriptor_name":"5' Flanking Region","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D045744","descriptor_name":"Cell Line, Tumor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1007/s00280-014-2476-y","doi":"https://doi.org/10.1007/s00280-014-2476-y","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s00280-014-2476-y","pdf_url":"https://link.springer.com/content/pdf/10.1007/s00280-014-2476-y.pdf","source":{"id":"https://openalex.org/S117498271","display_name":"Cancer Chemotherapy and Pharmacology","issn_l":"0344-5704","issn":["0344-5704","1432-0843"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Chemotherapy and Pharmacology","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:4077254","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4077254","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Chemother Pharmacol","raw_type":"Text"},{"id":"pmid:24832107","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/24832107","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer chemotherapy and pharmacology","raw_type":"Comparative Study"},{"id":"pmh:oai:CiteSeerX.psu:10.1.1.774.7009","doi":null,"is_oa":false,"landing_page_url":"http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.774.7009","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"ftp://ftp.ncbi.nlm.nih.gov/pub/pmc/e9/21/280_2014_Article_2476.PMC4077254.pdf","raw_type":"text"}],"best_oa_location":{"id":"doi:10.1007/s00280-014-2476-y","doi":"https://doi.org/10.1007/s00280-014-2476-y","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s00280-014-2476-y","pdf_url":"https://link.springer.com/content/pdf/10.1007/s00280-014-2476-y.pdf","source":{"id":"https://openalex.org/S117498271","display_name":"Cancer Chemotherapy and Pharmacology","issn_l":"0344-5704","issn":["0344-5704","1432-0843"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Chemotherapy and Pharmacology","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9763000011444092}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2010859136.pdf","grobid_xml":"https://content.openalex.org/works/W2010859136.grobid-xml"},"referenced_works_count":52,"referenced_works":["https://openalex.org/W1512179335","https://openalex.org/W1568678893","https://openalex.org/W1654947539","https://openalex.org/W1847718775","https://openalex.org/W1964963969","https://openalex.org/W1967156938","https://openalex.org/W1968035106","https://openalex.org/W1970383168","https://openalex.org/W1970961784","https://openalex.org/W1972071205","https://openalex.org/W1977118826","https://openalex.org/W1977285033","https://openalex.org/W1978389424","https://openalex.org/W1980816809","https://openalex.org/W1980945502","https://openalex.org/W1981625398","https://openalex.org/W1985746847","https://openalex.org/W1999686085","https://openalex.org/W2000143502","https://openalex.org/W2006167464","https://openalex.org/W2010333278","https://openalex.org/W2011836061","https://openalex.org/W2012867962","https://openalex.org/W2026487457","https://openalex.org/W2027325467","https://openalex.org/W2045119544","https://openalex.org/W2051868632","https://openalex.org/W2057519110","https://openalex.org/W2058591356","https://openalex.org/W2059306569","https://openalex.org/W2066580298","https://openalex.org/W2093715817","https://openalex.org/W2097521277","https://openalex.org/W2099343472","https://openalex.org/W2104987742","https://openalex.org/W2111471857","https://openalex.org/W2112591674","https://openalex.org/W2116259955","https://openalex.org/W2117897121","https://openalex.org/W2120415962","https://openalex.org/W2121481176","https://openalex.org/W2125079242","https://openalex.org/W2128183109","https://openalex.org/W2129272684","https://openalex.org/W2135566609","https://openalex.org/W2137913086","https://openalex.org/W2143743183","https://openalex.org/W2144149602","https://openalex.org/W2152367628","https://openalex.org/W2156402278","https://openalex.org/W2159164310","https://openalex.org/W2241547882"],"related_works":["https://openalex.org/W1979641337","https://openalex.org/W2088367588","https://openalex.org/W2415624398","https://openalex.org/W4394927021","https://openalex.org/W3083448534","https://openalex.org/W1987776622","https://openalex.org/W2557961665","https://openalex.org/W2067014924","https://openalex.org/W2957297183","https://openalex.org/W2340251168"],"abstract_inverted_index":{"PNT100":[0,25,42,55,99],"is":[1,10,41,44,135],"a":[2,13,35,114],"24-base,":[3],"chemically":[4],"unmodified":[5],"DNA":[6,38],"oligonucleotide":[7],"sequence":[8,96],"that":[9,43],"complementary":[11],"to":[12,24,51,140],"region":[14],"upstream":[15],"of":[16,21,29,67,98],"the":[17,54,68],"BCL-2":[18],"gene.":[19],"Exposure":[20],"tumor":[22],"cells":[23],"results":[26],"in":[27,46,71,74,113,129,132,146],"suppression":[28],"proliferation":[30],"and":[31,64,73,91,108,121,143,154],"cell":[32],"death":[33],"by":[34],"process":[36],"called":[37],"interference.":[39],"PNT2258":[40,76,134],"encapsulated":[45,112],"protective":[47],"amphoteric":[48],"liposomes":[49],"developed":[50],"efficiently":[52],"encapsulate":[53],"oligonucleotide,":[56],"provide":[57],"enhanced":[58],"serum":[59],"stability,":[60],"optimized":[61],"pharmacokinetic":[62],"properties":[63],"antitumor":[65,79,144],"activity":[66,80,128,145],"nanoparticle":[69],"both":[70],"vivo":[72,130],"vitro.":[75,133],"demonstrates":[77],"broad":[78],"against":[81,102],"BCL-2-driven":[82],"WSU-DLCL2":[83],"lymphoma,":[84],"highly":[85],"resistant":[86],"A375":[87],"melanoma,":[88],"PC-3":[89],"prostate,":[90],"Daudi-Burkitt's":[92],"lymphoma":[93,153],"xenografts.":[94],"The":[95],"specificity":[97],"was":[100],"demonstrated":[101],"three":[103],"control":[104,122],"sequences":[105,123],"(scrambled,":[106],"mismatched,":[107],"reverse":[109],"complement)":[110],"all":[111],"lipid":[115],"formulation":[116],"with":[117,148],"identical":[118],"particle":[119],"characteristics,":[120],"did":[124],"not":[125],"demonstrate":[126],"antiproliferative":[127],"or":[131,150],"currently":[136],"undergoing":[137],"clinical":[138],"testing":[139],"evaluate":[141],"safety":[142],"patients":[147],"recurrent":[149],"refractory":[151],"non-Hodgkin's":[152],"additional":[155],"studies":[156],"are":[157],"planned.":[158]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":4},{"year":2016,"cited_by_count":5},{"year":2015,"cited_by_count":2}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2016-06-24T00:00:00"}